Path: utzoo!utgpu!watmath!uunet!bionet!nihcu.bitnet!CZJ From: CZJ@nihcu.bitnet Newsgroups: bionet.sci-resources Subject: (none) Message-ID: <8901070148.AA10248@net.bio.net> Date: 4 Jan 89 23:05:39 GMT Sender: daemon@NET.BIO.NET Lines: 230 Attached is the Table of Contents and items of interest from the NIH Guide to Grants and Contracts 12/30/88. Jim Cassatt Vol. 17, No. 44, December 30, 1988 NOTICES SUPERCOMPUTING RESOURCES AVAILABLE TO BIOMEDICAL RESEARCHERS AT THE PITTSBURGH SUPERCOMPUTING CENTER .........(83/105)........ 1 Division of Research Resources Index: RESEARCH RESOURCES DATED ANNOUNCEMENTS (RFAs AND RFPs) NOTICE OF AVAILABILITY OF SUPPLEMENTAL DRUG ABUSE RESEARCH FUNDS ..(111/159). 1 National Institute on Drug Abuse Index: DRUG ABUSE ADAMHA SMALL INSTRUMENTATION GRANT PROGRAM ................(161/264)......... 2 Alcohol, Drug Abuse, and Mental Health Administration Index: ALCOHOL, DRUG ABUSE, MENTAL HEALTH DRUG RESISTANCE AND THE HUMAN IMMUNODEFICIENCY VIRUS (RFA) ...(267/393)...... 3 National Institute of Allergy and Infectious Diseases (1204/1556) Index: ALLERGY, INFECTIOUS DISEASES STATISTICAL ISSUES IN AIDS RESEARCH (RFA) .............(401/436, 1559/1801).. 5 National Institute of Allergy and Infectious Diseases Index: ALLERGY, INFECTIOUS DISEASES ANTIBODY DEPENDENT ENHANCEMENT OF LENTIVIRUS INFECTION: IMPLICATIONS FOR AIDS VACCINE DEVELOPMENT (RFA) .......(439/478, 1804/2038).. 5 National Institute of Allergy and Infectious Diseases Index: ALLERGY, INFECTIOUS DISEASES THE ROLE OF CARBOHYDRATE IN IMMUNOLOGIC RESPONSE TO THE ENVELOPE GLYCOPROTEINS OF HIV OR RELATED IMMUNODEFICIENCY VIRUSES (RFA) ..(481/516)... 6 National Institute of Allergy and Infectious Diseases (2041/2296) Index: ALLERGY, INFECTIOUS DISEASES MOLECULAR BASIS FOR THE SELECTIVITY OF DIFFERENT ANTIVIRAL THERAPIES (RFA) .. 6 National Institute of Allergy and Infectious Diseases (519/639, 2299/2565) Index: ALLERGY, INFECTIOUS DISEASES ONGOING PROGRAM ANNOUNCEMENTS STUDIES OF SUICIDE AND SUICIDAL BEHAVIOR ....................(644/717)....... 8 National Institute of Mental Health Index: MENTAL HEALTH ADAMHA SCIENTIST DEVELOPMENT AWARD and ADAMHA SCIENTIST DEVELOPMENT AWARD FOR CLINICIANS ............................(721/817)....... 9 Alcohol, Drug Abuse, and Mental Health Administration Index: ALCOHOL, DRUG ABUSE, MENTAL HEALTH INVESTIGATIONS INTO THE PATHOLOGY AND PATHOGENESIS OF INTERSTITIAL CYSTITIS: A CHRONIC, INFLAMMATORY DISORDER OF THE URINARY BLADDER .........10 National Institute of Diabetes and Digestive and Kidney Diseases Index: DIABETES, DIGESTIVE AND KIDNEY DISEASES (820/980) RESEARCH ON ECONOMIC AND SOCIOECONOMIC ISSUES IN THE PREVENTION, TREATMENT, AND EPIDEMIOLOGY OF ALCOHOL ABUSE AND ALCOHOLISM ..(983/1192).....12 National Institute on Alcohol Abuse and Alcoholism Index: ALCOHOL ABUSE, ALCOHOLISM NOTICES SUPERCOMPUTING RESOURCES AVAILABLE TO BIOMEDICAL RESEARCHERS AT THE PITTSBURGH SUPERCOMPUTING CENTER Division of Research Resources Grants are available to enable biomedical researchers to use the Pittsburgh Supercomputing Center's (PSC) Cray Y-MP/832 through a program funded by the Biomedical Research Technology Program, Division of Research Resources. Starter grants of 3 service units are available for feasibility studies or code conversion and optimization. A limited number of larger grants are also available to experienced supercomputing researchers. Prospective grantees should demonstrate a need for supercomputing facilities; the proposed research must be biomedical and non-proprietary; grantees must be faculty members or post-doctoral fellows. Graduate students may be designated as users on any grant. For application forms and additional information, call or send mail to: Cherolyn A. Brooks User Services, Pittsburgh Supercomputing Center 4400 Fifth Avenue Pittsburgh, Pennsylvania 15213 Telephone: (412) 268-5206, or 1-800-222-9310 (Pennsylvania); 1-800-221-1641 (outside Pennsylvania). MOLECULAR BASIS FOR THE SELECTIVITY OF DIFFERENT ANTIVIRAL THERAPIES RFA AVAILABLE: AI-89-10 National Institute of Allergy and Infectious Diseases LETTER OF INTENT: February 1, 1989 APPLICATION RECEIPT DATE: MARCH 28, 1989 The National Institute of Allergy and Infectious Diseases (NIAID) is playing a central role in investigating methods to treat viral diseases including the Acquired Immunodeficiency Syndrome (AIDS). The only drug currently approved for treatment of AIDS is a nucleoside analogue, zidovudine (3'-azido-3'-deoxythymidine, AZT). Zidovudine and other drugs presently targeted for introduction into clinical trials or already in clinical trials are analogues of endogenous substances. These analogues are metabolized by the same metabolic pathways and utilize the same precursor/cofactor pools as the normal endogenous substances. The optimum therapeutic agent will be that one which produces the highest intracellular concentration of antiviral agent without disrupting the normal function/cycling of the analogous endogenous substances. The targeted development of optimal nucleoside analogues is dependent upon a thorough understanding of the effect of the therapeutic agent on endogenous purine/pyrimidine pools and activity of enzymes involved in the formation/utilization of these pools. The presence and activity of these components, however, is highly dependent upon cell type and hence aggressive research is required to define the kinetics of metabolism of nucleosides and other endogenous cellular components in various cell types from different research animals and to investigate the complex interrelationship between therapeutic analogues and their endogenous counterparts. OBJECTIVES AND SCOPE The NIAID invites applications for research grants to investigate molecular mechanisms of action of potential AIDS therapies and how these agents interact with endogenous metabolic pathways that metabolize the therapeutic agents. Investigators are encouraged to: (a) study kinetics of intracellular metabolism of endogenous substances and how potential therapies affect this normal metabolism; (b) study the metabolism of potential therapeutic agents Vol. 17, No. 44, December 30, 1988 - Page 6 and the selective distribution of those metabolites to target tissues in the body; and (c) study the potential interactions that may occur at the molecular level when two or more potential therapies are used in combination. Our understanding of how therapeutic interventions potentially interact with normal intracellular metabolism and function has been insufficiently studied and only recently appreciated for its potential importance. Thus the feedback inhibition exerted by zidovudine triphosphate on the size and utilization of thymidine triphosphate pools is only now being appreciated for its potential effect on cell viability and function. The difference in such interactions in virus infected and noninfected cells may form the basis for a differential effect of certain specifically targeted antiviral agents. However, prior to the optimum development of specific antiviral therapies, it is necessary to understand the kinetics and mechanics of intracellular metabolites/metabolism which might be affected by the potential therapy. An understanding of such molecular metabolism is the objective of this RFA. Complicating the development of specifically targeted antiviral therapy drugs is the fact that the size and kinetics of various metabolic pools differs among various cell types. Thus the kinetics of purine metabolism, for example, may differ from bone marrow precursor cells to macrophages to epithelial cells of the gastrointestinal tract. A thorough understanding of the differences in intracellular metabolism among the various target cells of the AIDS virus and thus the target of potential therapies, is essential for any targeted drug development program to succeed. Letter of Intent: Prospective applicants are encouraged to submit a one-page letter of intent that includes a brief description of the thrust of the research activities and identity of the principal investigator or other key personnel, if known. The Institute requests such letters for the purpose of providing an indication of the number and scope of applications to be received. A letter of intent is not binding, will not enter into the review of any application subsequently submitted, and is not a necessary requirement for application. APPLICATION SUBMISSION Eligibility: Universities, medical colleges, hospitals, and laboratories or other public, private or for-profit institutions are eligible. Submission: Use the regular research grant application form PHS 398 that is available in business offices of most research institutions or from the Division of Research Grants (DRG), NIH. To identify responses to this announcement, check "yes" and put "MOLECULAR BASIS FOR SELECTIVITY OF DIFFERENT ANTIVIRAL THERAPIES" under item 2 on page l of the grant application. THE RFA LABEL AVAILABLE IN THE 9/86 REVISION OF THE APPLICATION FORM 398 MUST BE AFFIXED TO THE BOTTOM OF THE FACING PAGE. The complete original application and 32 copies should be mailed to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, Maryland 20892** Applications must be received by March 28, l989. MECHANISM OF SUPPORT The NIAID is expected to receive primary assignment on all applications submitted in response to this RFA and has allocated $440,000 for the initial year of funding of applications received in response to this RFA. Two to four awards are anticipated although the number of awards to be made is dependent upon receipt of a sufficient number of applications of high scientific merit and the uniqueness and diversity of the proposals received. The earliest possible award date is September 30, 1989. INQUIRIES A more detailed RFA may be obtained from: Charles L. Litterst, Ph.D., Acting Head, Drug Development Section Developmental Therapeutics Branch, AIDS Program National Institute of Allergy and Infectious Diseases 6003 Executive Boulevard Bethesda, Maryland 20892 Telephone: (301) 496-0636